PCRX vs. AGIO, OPK, ALXO, AVIR, ADCT, PRGO, CORT, SUPN, NKTR, and OMER
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Agios Pharmaceuticals (AGIO), OPKO Health (OPK), ALX Oncology (ALXO), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Perrigo (PRGO), Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), and Omeros (OMER). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.
Pacira BioSciences has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
Pacira BioSciences has a net margin of 10.34% compared to Agios Pharmaceuticals' net margin of -1,199.26%. Pacira BioSciences' return on equity of 12.98% beat Agios Pharmaceuticals' return on equity.
Pacira BioSciences received 332 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. Likewise, 71.81% of users gave Pacira BioSciences an outperform vote while only 67.61% of users gave Agios Pharmaceuticals an outperform vote.
99.7% of Pacira BioSciences shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by company insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Pacira BioSciences presently has a consensus price target of $47.40, indicating a potential upside of 57.74%. Agios Pharmaceuticals has a consensus price target of $35.00, indicating a potential downside of 9.82%. Given Pacira BioSciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Pacira BioSciences is more favorable than Agios Pharmaceuticals.
Pacira BioSciences has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Agios Pharmaceuticals had 15 more articles in the media than Pacira BioSciences. MarketBeat recorded 19 mentions for Agios Pharmaceuticals and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.33 beat Agios Pharmaceuticals' score of 0.57 indicating that Pacira BioSciences is being referred to more favorably in the media.
Summary
Pacira BioSciences beats Agios Pharmaceuticals on 15 of the 18 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
